Budesonide/formoterol: in chronic obstructive pulmonary disease

Area of Science:

• Respiratory Medicine
• Clinical Pharmacology

Background:

• Severe chronic obstructive pulmonary disease (COPD) poses a significant global health burden.
• Effective management strategies are crucial for improving patient outcomes and quality of life.

Purpose of the Study:

• To evaluate the efficacy and safety of budesonide/formoterol combination therapy in patients with severe COPD.
• To assess the impact of budesonide/formoterol on lung function, exacerbation rates, and quality of life.

Main Methods:

• Two large, randomized, double-blind, 12-month studies were conducted.
• Patients with severe COPD received budesonide/formoterol 320/9 microg twice daily via Turbuhaler.
• Comparisons were made against budesonide alone, formoterol alone, and placebo.

Main Results:

• Budesonide/formoterol significantly increased forced expiratory volume in 1 second (FEV1) and peak expiratory flow compared to budesonide or placebo.
• The rate of COPD exacerbations and those requiring oral corticosteroids was significantly reduced with budesonide/formoterol versus formoterol and placebo.
• Health-related quality of life scores improved significantly with budesonide/formoterol compared to placebo.
• Time to first exacerbation was significantly prolonged with budesonide/formoterol.

Conclusions:

• Budesonide/formoterol is an effective treatment for severe COPD, improving lung function and reducing exacerbations.
• The combination therapy demonstrates significant benefits in quality of life for COPD patients.
• Budesonide/formoterol was well-tolerated, with a safety profile similar to its individual components.